PAHC vs. ALVO, RXRX, SRRK, IMVT, AKRO, APLS, ACLX, RYTM, VKTX, and ACAD
Should you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Scholar Rock (SRRK), Immunovant (IMVT), Akero Therapeutics (AKRO), Apellis Pharmaceuticals (APLS), Arcellx (ACLX), Rhythm Pharmaceuticals (RYTM), Viking Therapeutics (VKTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.
Phibro Animal Health vs.
Phibro Animal Health (NASDAQ:PAHC) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking.
99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 0.5% of Alvotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Phibro Animal Health has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health received 308 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 60.11% of users gave Phibro Animal Health an outperform vote while only 50.00% of users gave Alvotech an outperform vote.
Phibro Animal Health currently has a consensus price target of $21.00, indicating a potential downside of 14.36%. Alvotech has a consensus price target of $18.00, indicating a potential upside of 62.16%. Given Alvotech's stronger consensus rating and higher possible upside, analysts clearly believe Alvotech is more favorable than Phibro Animal Health.
Phibro Animal Health has a net margin of 1.75% compared to Alvotech's net margin of -123.47%. Phibro Animal Health's return on equity of 25.35% beat Alvotech's return on equity.
Phibro Animal Health has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.
In the previous week, Phibro Animal Health had 3 more articles in the media than Alvotech. MarketBeat recorded 5 mentions for Phibro Animal Health and 2 mentions for Alvotech. Phibro Animal Health's average media sentiment score of 0.90 beat Alvotech's score of 0.81 indicating that Phibro Animal Health is being referred to more favorably in the media.
Summary
Phibro Animal Health beats Alvotech on 14 of the 18 factors compared between the two stocks.
Get Phibro Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phibro Animal Health Competitors List
Related Companies and Tools
This page (NASDAQ:PAHC) was last updated on 3/4/2025 by MarketBeat.com Staff
